AccessibilityHelp
Innoviva logo

Innoviva(NASDAQ) INVA

Market Cap$1.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+52%
5 Year+27%
1 Year+13%
1 Month+2%
Premium Feature
Moneyball Superscore
71/100
$20.64
-1.99%
-0.42Today
After hours$20.64+$0.00 (+0.00%)
Innoviva last closing stock price
MetricPriceDate
Last closeUSD 20.662026-10-23
Innoviva stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.58%USD 20.782026-10-16
1 month+2.08%USD 20.242026-09-23
3 month-3.64%USD 21.442026-07-24
Year to date+3.35%USD 19.992025-12-31
1 year+13.14%USD 18.262025-10-23
3 year+62.42%USD 12.722023-10-24
5 year+27.22%USD 16.242021-10-22
Since inception+52.11%USD 13.582004-10-05

Innoviva Financials at a Glance

Market Cap

$1.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$443.43M

Net Income (TTM)

$357.24M

EPS (TTM)

$4.10

P/E Ratio

5.03

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$20.64

Volume

978,553.271

Open

$20.88

Previous Close

$20.66

Daily Range

$20.51 - $20.94

52-Week Range

$17.45 - $25.15

Estimated Earnings Date

Nov 4, 2026

INVA News

BuyAlert-Green.png

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Jonathan PoncianoMay 29, 2026
Foolcom-Featured.png

Innoviva (INVA) Q2 Sales Jump 64%

Motley Fool Markets TeamAug 6, 2025
GettyImages-943401146

3 Small-Cap Stocks With Big-Cap Potential

Alex CarchidiSep 25, 2020
GettyImages-1064259834

2 Best Biotech Stocks to Buy in August

Alex CarchidiAug 9, 2020
people working in a lab

2 Incredibly Cheap Biotech Stocks

David Jagielski, CPADec 23, 2019
Microscope (2)

3 Top Biotech Stocks to Buy in April

George Budwell, PhDApr 8, 2019
Curious Man Reading Financial Newspaper Getty

3 Under-the-Radar Value Stocks to Buy in 2019

Sean WilliamsJan 1, 2019
Stethoscope Over Money Healthcare Costs Obamacare Getty

13 of the Cheapest Healthcare Stocks

Sean WilliamsAug 14, 2018
Page 1

INVA: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innoviva

Innoviva, Inc. NASDAQ:INVA earns royalties from medicines that help people breathe. It also sells specialized treatments for serious hospital-based infections. The company invests in other businesses to create new medical solutions.

Medicines and Medical Portfolios

  • Respiratory Assets: Royalties from Glaxo Group Limited on medications like RELVAR/BREO ELLIPTA and ANORO ELLIPTA for lung conditions.
  • Critical Care Products: Hospital-focused treatments such as GIAPREZA for distributive shock and XACDURO for bacterial pneumonia.
  • Infectious Disease Treatments: Antibiotics including XERAVA for abdominal infections and ZEVTERA for skin and blood infections.
  • Oral Delivery Platform: LYNX technology designed to turn daily oral medicines into weekly or monthly doses.

Strategic Growth and Expansion

  • Launched Nortiva Bio in the second quarter of 2026 to advance the LYNX long-acting oral drug delivery platform.
  • Entered an exclusive agreement with Dr. Reddy's Laboratories in the second quarter of 2026 to commercialize XACDURO in South and Central America.
  • Commercially launched the antibiotic ZEVTERA in the third quarter of 2025 for treating serious bacterial infections.
  • Obtained FDA approval for NUZOLVENCE on Dec. 12, 2025, for the treatment of uncomplicated urogenital gonorrhea.

A Differentiated Business Model

Innoviva operates a dual-revenue model that combines steady royalty streams with an active, hospital-focused specialty therapeutics platform. Its disciplined capital allocation strategy involves investing in external healthcare assets, such as Armata Pharmaceuticals, to target significant unmet medical needs.

Performance by the Numbers

  • Total revenue reached $119.6 million in the second quarter of 2026, up 19% year over year.
  • Net product sales grew to $51.8 million in the second quarter of 2026, up 46% year over year.
  • The company reported a net loss of $83.4 million in the second quarter of 2026, primarily due to a $161.0 million drop in the fair value of investments.
  • Cash and cash equivalents totaled $570.4 million as of June 30, 2026.
  • Innoviva repurchased 1,403,247 shares for $31.4 million during the second quarter of 2026.

The Evolution of Innoviva

Innoviva has transformed from a pure royalty-based business into a diversified healthcare company with its own operating platform. Its focus on critical care and infectious diseases complements its stable income from respiratory treatment partnerships.

AI Generated • Aug 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

159

CEO

Pavel Raifeld, CFA, MBA

Website

www.inva.com

Headquarters

Burlingame, CA 94010, US

INVA Financials

Key Financial Metrics (TTM)

Gross Margin

73.09%

Operating Margin

36.66%

Net Income Margin

80.56%

Return on Equity

30.03%

Return on Capital

11.36%

Return on Assets

20.98%

Earnings Yield

19.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

72.25M

Volume

978.55K

Avg. Volume

770.81K

Financials (TTM)

Gross Profit

$324.09M

Operating Income

$162.58M

EBITDA

$770.49M

Operating Cash Flow

$191.49M

Capital Expenditure

-$3.17M

Free Cash Flow

$188.32M

Cash & ST Invst.

$579.06M

Total Debt

$269.66M

Innoviva Performance Analysis

Innoviva annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,508,000-98.6%
20232023-12-31USD 324,263,0005787.1%
20242024-12-31USD 372,511,00014.9%
20252025-12-31USD 425,128,00014.1%
Innoviva sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.5%
Q42025-12-319.5%
Q12026-03-31-17.0%
Q22026-06-3022.0%
Innoviva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.08N/A
20232023-12-31USD 2.20N/A
20242024-12-31USD 0.36-83.6%
20252025-12-31USD 3.30811.7%
Innoviva sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3040.3%
Q42025-12-3179.6%
Q12026-03-3114.4%
Q22026-06-30-151.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$119.59M

+19.3%

Gross Profit

$90.62M

+1.0%

Gross Margin

75.77%

N/A

Market Cap

$1.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.39M

N/A

Employees

159

N/A

Net Income

-$83.42M

-231.0%

EBITDA

$214.41M

+155.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$579.06M

+16.3%

Total Debt

$269.66M

-40.2%

Accounts Receivable

$110.62M

+25.3%

Inventory

$38.97M

-20.5%

Long Term Debt

$268.95M

+4.2%

Short Term Debt

$712.00K

-99.6%

Return on Assets

20.98%

N/A

Return on Invested Capital

9.82%

N/A

Free Cash Flow

$51.54M

+16.9%

Operating Cash Flow

$51.97M

+17.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TBPHTheravance Biopharma Inc
$17.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About INVA

What is the current price of Innoviva?

Innoviva is trading at $20.66 per share.

What is the 52-week range for Innoviva?

Over the past 52 weeks, Innoviva has traded between $17.45 and $25.15.

How much debt does Innoviva have?

As of the most recent reporting period, Innoviva reported total debt of $269.66M.

How much cash does Innoviva have on hand?

Innoviva reported $570.39M in cash and cash equivalents in its most recent financial results.

What is Innoviva’s dividend yield?

Innoviva does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services